


PHARMACEUTICAL 2018

REVANCE

## Revance Therapeutics Inc. Rank 143 of 349







PHARMACEUTICAL 2018

## Revance Therapeutics Inc. Rank 143 of 349

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 337% points. The greatest weakness of Revance Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -120%, being 157% points above the market average of -278%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 285,211           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 20,902            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 1,238             |
| Other Compr. Net Income                     | 45                |
| Other Expenses                              | 3,384             |
| Other Liabilities                           | 5,952             |
| Other Net Income                            | 294               |
| Property and Equipment                      | 9,250             |
| Research and Development                    | 80,361            |
| Revenues                                    | 262               |
| Selling, General and Administrative Expense | 37,398            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 295,699           |
| Liabilities              | 26,854            |
| Expenses                 | 121,143           |
| Stockholders Equity      | 268,845           |
| Net Income               | -120,587          |
| Comprehensive Net Income | -120,564          |
| Economic Capital Ratio   | -120%             |

